rofecoxib has been researched along with Helicobacter Infections in 11 studies
Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eight thousand seventy-six rheumatoid arthritis patients aged >or=50 years (or >or=40 on corticosteroid therapy) were randomly assigned to rofecoxib 50 mg daily or naproxen 500 mg twice daily for a median of 9 months." | 5.10 | Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. ( Bombardier, C; Brett, C; Davis, B; Hawkey, CJ; Laine, L; Reicin, A; Shapiro, D, 2002) |
| " Rofecoxib taken at supra-therapeutic dosage was recognised to increase the incidence of myocardial infarction." | 3.72 | [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. ( Lamarque, D, 2004) |
| " Dosing should be [figure: see text] cautious in old patients, however, because of the ability of NSAIDs and coxibs to cause fluid retention, heart failure, and hypertension." | 2.41 | Gastrointestinal safety of COX-2 specific inhibitors. ( Hawkey, CJ; Jones, JI, 2001) |
| "In indomethacin and rofecoxib-treated gerbils, the following results were obtained in H pylori-infected group vs H pylori-eradicated group respectively: hyperplasia area of the stomach (mm2): 82." | 1.33 | Eradication of Helicobacter pylori significantly reduced gastric damage in nonsteroidal anti-inflammatory drug-treated Mongolian gerbils. ( Chang, CC; Chen, SH; Fang, CL; Hsieh, CR; Lien, GS; Lou, HY; Pan, S, 2005) |
| "Twenty-four gastric cancer (GC) patients entered this study and were examined twice, once before and then following a 14-day treatment with Vioxx at a dose of 25 mg twice daily." | 1.32 | Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients. ( Bielanski, W; Hahn, EG; Hartwich, A; Kania, J; Konturek, PC; Konturek, SJ; Rehfeld, JF; Zuchowicz, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Laine, L | 1 |
| Bombardier, C | 1 |
| Hawkey, CJ | 2 |
| Davis, B | 1 |
| Shapiro, D | 1 |
| Brett, C | 1 |
| Reicin, A | 1 |
| Lehmann, FS | 1 |
| Gyr, N | 1 |
| Scheiman, JM | 1 |
| Greenson, JK | 1 |
| Lee, J | 1 |
| Cryer, B | 1 |
| Konturek, PC | 1 |
| Konturek, SJ | 1 |
| Bielanski, W | 1 |
| Kania, J | 1 |
| Zuchowicz, M | 1 |
| Hartwich, A | 1 |
| Rehfeld, JF | 1 |
| Hahn, EG | 1 |
| Kanatani, K | 1 |
| Ebata, M | 1 |
| Murakami, M | 1 |
| Okabe, S | 1 |
| Lamarque, D | 1 |
| Chang, CC | 1 |
| Chen, SH | 1 |
| Lien, GS | 1 |
| Lou, HY | 1 |
| Hsieh, CR | 1 |
| Fang, CL | 1 |
| Pan, S | 1 |
| Ebert, MP | 1 |
| Schäfer, C | 1 |
| Chen, J | 1 |
| Hoffmann, J | 1 |
| Gu, P | 1 |
| Kubisch, C | 1 |
| Carl-McGrath, S | 1 |
| Treiber, G | 1 |
| Malfertheiner, P | 1 |
| Röcken, C | 1 |
| McCarthy, DM | 1 |
| Jones, JI | 1 |
| Miyake, K | 1 |
| Sakamoto, C | 1 |
4 reviews available for rofecoxib and Helicobacter Infections
| Article | Year |
|---|---|
[The future of peptic ulcer disease without Helicobacter].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin | 2003 |
Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Cyclooxygenase Inhibitors; Diclofenac; Gas | 2002 |
Gastrointestinal safety of COX-2 specific inhibitors.
Topics: Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygena | 2001 |
[Prophylaxis against non-steroidal anti-inflammatory drug-associated ulcers and erosions].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygena | 2002 |
1 trial available for rofecoxib and Helicobacter Infections
| Article | Year |
|---|---|
Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis.
Topics: Adrenal Cortex Hormones; Adult; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Art | 2002 |
6 other studies available for rofecoxib and Helicobacter Infections
| Article | Year |
|---|---|
Effect of cyclooxygenase-2 inhibition on human Helicobacter pylori gastritis: mechanisms underlying gastrointestinal safety and implications for cancer chemoprevention.
Topics: Adult; Cell Division; Cyclooxygenase 2; Dinoprostone; Endoscopy, Gastrointestinal; Female; Follow-Up | 2003 |
Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients.
Topics: Aged; Apoptosis; Case-Control Studies; Caspase 3; Caspases; Cyclooxygenase 2; Cyclooxygenase 2 Inhib | 2003 |
Effects of indomethacin and rofecoxib on gastric mucosal damage in normal and Helicobacter pylori-infected mongolian gerbils.
Topics: Administration, Oral; Animals; Dinoprostone; Drug Administration Schedule; Drug Synergism; Gastric A | 2004 |
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2004 |
Eradication of Helicobacter pylori significantly reduced gastric damage in nonsteroidal anti-inflammatory drug-treated Mongolian gerbils.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Chronic Diseas | 2005 |
Protective role of heat shock protein 27 in gastric mucosal injury.
Topics: Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; | 2005 |